4 Year Follow-Up Results Checkmate 214

nivolumab combined with ipilimumab versus sunitinib

extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020 Nov;5(6):e001079.


in previously untreated advanced or metastatic renal cell carcinoma






Trial Design

Trial Sites



source: Albiges L, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma:



Patients with favourable risk

Objective Response Rate (ORR)

29.6% vs 51.6% % of Patients with Partial or Complete Response

Progression Free Survival (PFS)

12.4 Months



Complete Response

Median

12.0% vs 6.5%

Overall Survival

not reached yet

not reached yet

Duration of Response:

not reached yet

33.2 Months

Objective

Patients with intermediate/poor risk

Response Rate (ORR)

41.9% vs 26.8%

Free Survival (PFS)

Progression

11.2 Months

8.3 Months

Median Overall Survival

48.1 Months

26.6 Months

Response

Complete

10.4% 1.4%

Response:


Duration of

19.7 Months

not reached yet

Grade 3 or

Grade 4





www.ikcc.org